Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib induction therapy in moderate to severe Crohn's disease
NL-OMON39768Phase 2Active, not recruiting
- Sponsor
- Pfizer
- Start
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tofacitinib in Crohn's disease and inflammatory bowel disease (IBD) (3 arms), sponsored by Pfizer. Primary endpoint: Clinical remission at Week 8. Started May 2014; status: active, not recruiting.
02
Drugs
03
Conditions
Crohn's diseaseinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NL-OMON39768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39768.